Loading stock data…
GRAL
$60.90-0.62 (-1.01%)
Market ClosedLast close Jun 9
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GRAIL, Inc. in the Healthcare sector is trading at $60.90 with a market capitalization of $2.6B. Wall Street consensus targets $66.00 (8 analysts), implying a +8.4% move over the next 12 months. The stock is currently 49% below its 52-week high of $118.84, remaining 13.6% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +8.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$60.90
Potential Downside
0%
Whystock Fair Value$60.90
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Buy
Mean target$66.00+8.4%
Range$56.00 – $80.00
Fundamentals
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.62B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-15.81%
Volume
Today's trading volume
545,534
Recent News
Honeywell Stock Is Likely to Reward Shareholders Following Quantinuum IPO, Split
HON will own a large stake in Quantinuum following the IPO.
A Look At GRAIL (GRAL) Valuation After A Sharp One Day Share Price Drop
GRAIL stock reaction and recent performance GRAIL (GRAL) shares recently moved after a single day decline of about 10%, drawing attention to how the stock’s sharp daily move compares with its gains over the past month and past 3 months. See our latest analysis for GRAIL. That 10.16% one day share price drop comes after a 19.13% 30 day share price return and a 22.06% 90 day share price return. Yet year to date the share price is still down 27.53%, even as the 1 year total shareholder return...
Grail Plummets On Mixed Results For Cancer-Screening Blood Test
Grail stock plummeted Monday on mixed results for its landmark study, comparing blood test Galleri with traditional cancer screening methods.
GRAIL (GRAL) Is Up 6.7% After Mixed Galleri Trial Data At ASCO 2026 - Has The Bull Case Changed?
At the 2026 ASCO Annual Meeting, GRAIL reported full results from the NHS-Galleri and PATHFINDER 2 studies, showing its Galleri blood test shifted cancer detection toward earlier stages and reduced Stage IV diagnoses by over 20% in later screening rounds, while maintaining strong performance and a favorable safety profile. An important nuance is that although NHS-Galleri highlighted earlier detection benefits, it did not meet its primary endpoint of reducing the combined incidence of Stage...
GRAIL, Inc. (GRAL): One of the Best Stock Picks of Jeff Bezos
We just covered the Jeff Bezos Stock Portfolio: Top 10 Stock Picks and GRAIL, Inc. (NASDAQ:GRAL) ranks 8th on this list. The interest of Jeff Bezos in GRAIL, Inc. (NASDAQ:GRAL) can be understood in context of the history of Bezos as a backer of disruptive, foundational healthcare platforms that use data computing. In January 2016, […]